Lutetium-177-PSMA I&T for progressing metastatic castrate-resistant prostate cancer : a single NZ centre experience
Loading...
Other Title
Authors
Vyas, Madhusudan
Fagan, J.
Lim, R.
Garett, N.
Fagan, J.
Lim, R.
Garett, N.
Author ORCID Profiles (clickable)
Degree
Grantor
Date
2020-10
Supervisors
Type
Conference Contribution - Oral Presentation
Ngā Upoko Tukutuku (Māori subject headings)
Keyword
cancer patients
prostate cancer
theranostics
radionuclide therapy
Lu-177
Lutetium-177
neuroendocrine tumours (NETs)
metastatic castration-resistant prostate cancer (mCRPC)
mCRPC
New Zealand
prostate cancer
theranostics
radionuclide therapy
Lu-177
Lutetium-177
neuroendocrine tumours (NETs)
metastatic castration-resistant prostate cancer (mCRPC)
mCRPC
New Zealand
ANZSRC Field of Research Code (2020)
Citation
Vyas, M., Fagan, J., Lim, R., & Garett, N. (2020, October). Lutetium-177-PSMA I&T for progressing metastatic castrate-resistant prostate cancer: A single NZ centre experience. Paper presented at the New Zealand Society for Oncology-2020, Auckland, New Zealand.
Abstract
Objectives
Metastatic Castration resistant prostate cancer (mCRPC)
Metastatic Castration resistant prostate cancer (mCRPC) and PSMA
Various PSMA ligands and radionuclidessuitable for labelling
Lu177-PSMA and Mechanism of therapy
First reported outcome for Lu177-PSMA-617
Inclusion criteria
Exclusion criteria
Treatment protocol
Response criterion
Results: Patient Characteristics
Results: Therapy outcomes
PSA Response
Haematoxicity
Quality of Life Outcomes
Feedback from patients
Image evaluation for therapy responses
Limitations
Future plan
Conclusion
References
Publisher
Permanent link
Link to ePress publication
DOI
Copyright holder
Authors
Copyright notice
All rights reserved